Pegilodecakin Plus FOLFOX Fails to Improve Outcomes in Metastatic PDAC
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Pancreatic Cancer
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
PERT Shows Promise in Unresected Pancreatic Cancer
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
Potential Markers for High Risk of Pancreatic Cancer Identified
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
Comparative Diagnostic Evaluation with Contrast-Enhanced Ultrasound, Computed Tomography and Magnetic Resonance Imaging in Patients with Pancreatic Cystic Neoplasms
[Cancer Management and Research] Researchers present a comparison study on the sensitivity and accuracy of 3 types of imaging studies — contrast-enhanced ultrasound, MRI, and computed tomography — in diagnosing and classifying pancreatic cystic neoplasms.
New-Onset Type 2 Diabetes as a Potential Biomarker in Pancreatic Cancer
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Clinical, Genetic, Biomarker Model IDs Risk for Pancreatic Cancer
Area under the ROC curve estimated by cross-validation was 0.62 for multifactor model.
Treatment Options for Pancreatic Neuroendocrine Tumors
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
Molecularly Matched Therapy Promising in Pancreatic Cancer
Overall survival significantly longer for patients with actionable molecular alterations receiving matched therapy.
- Loading...
Loading...
Next post in Pancreatic Cancer
Loading... 
Loading...